We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Fluorescence-Based Assay for Alzheimer's Research

By Biotechdaily staff writers
Posted on 07 Oct 2003
A new fluorescence-based assay utilizes a super-quenching polymer that offers greater sensitivity and specificity for high-throughput screening and drug discovery related to Alzheimer's disease.

A technique commonly used in screening new drug candidates is fluorescence resonance energy transfer (FRET), The new assay offers several advantages over conventional FRET. More...
Typically, FRET reactions couple a single fluorophore with a single quencher molecule. The new assay couples a quencher molecule with a fluorescent polymer chain. Each quencher alters fluorescence of several hundred fluorophores. This enhanced activity provides not only greater sensitivity and specificity but also takes less time for results and reduces costs.

The assay, called QTL Lightspeed Beta-Secretase Assay Kit, combines high sensitivity with high speed for screening potential inhibitors against beta-secretase. The major constituent of the senile plaques associated with Alzheimer's disease is the beta-amyloid peptide, generated by the activity of the enzyme beta-secretase in the brain. The assay is the product of QTL Biosystems, LLC (Santa Fe, NM, USA).

"Because the QTL Lightspeed Beta-Secretase Assay Kit generates a large signal, researchers will be able to generate results that offer better signal-to-noise ratio, more robustness, enhanced sensitivity, and quicker time to results, even at the highest throughput densities,” said Dunan McBranch, Ph.D., CEO of QTL Biosystems.




Related Links:
QTL Biosystems

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.